References
- Ho KM, Burrell M, Rao S, Baker R. Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. Br J Anaesth 2010;105: 596-602. https://doi.org/10.1093/bja/aeq254
- Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994;331:1601-1606. https://doi.org/10.1056/NEJM199412153312401
- Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S. https://doi.org/10.1378/chest.08-0656
- Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest 2003;124:357S-363S. https://doi.org/10.1378/chest.124.6_suppl.357S
- Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-707. https://doi.org/10.1056/NEJM199609053351003
- Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. Ann Surg 2010;251:393-396. https://doi.org/10.1097/SLA.0b013e3181b5d61c
- De A, Roy P, Garg VK, Pandey NK. Low-molecularweight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis. 2010;21:57-61. https://doi.org/10.1097/MBC.0b013e3283333505
- Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg 1997;85:874-885. https://doi.org/10.1213/00000539-199710000-00031
- Rutherford EJ, Schooler WG, Sredzienski E, Abrams JE, Skeete DA. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma 2005;58: 1167-1170. https://doi.org/10.1097/01.TA.0000172292.68687.44
- Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010;14:R41. https://doi.org/10.1186/cc8924
- Vivino G, Antonelli M, Moro ML, Cottini F, Conti G, Bufi M, et al. Risk factors for acute renal failure in trauma patients. Intensive Care Med 1998;24:808-814. https://doi.org/10.1007/s001340050670
- Gomes E, Antunes R, Dias C, Araujo R, Costa-Pereira A. Acute kidney injury in severe trauma assessed by RIFLE criteria: a common feature without implications on mortality? Scand J Trauma Resusc Emerg Med 2010;18:1. https://doi.org/10.1186/1757-7241-18-1
- Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-775. https://doi.org/10.1592/phco.20.9.771.35210
- Brophy DF, Martin EJ, Gehr TW, Carr ME Jr. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004;44:270-277. https://doi.org/10.1053/j.ajkd.2004.04.032
- Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-231. https://doi.org/10.1016/S0049-3848(02)00031-2
- Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci 2011;26:945-950. https://doi.org/10.3346/jkms.2011.26.7.945
- Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009;31:668-675. https://doi.org/10.3109/08860220903180616